secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001213900-26-052213
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX exits phage therapy, pivots to defense/security via DFSL and Zorronet acquisitions
--------------------------------------------------------------------------------

- Discontinued all clinical trials; former BiomX Ltd. subsidiary filed for insolvency in Israel in Dec 2025.
- Acquired 60% of DFSL (LADAR detection) and 100% of Zorronet (AI security platform) to enter defense markets.
- New management: Michael Oster as CEO, David Rokach as CFO appointed in Q1 2026.
- Established X Security & Defense subsidiary; committed over $3M for 2026 operations.
- Zorronet has projects with Elbit Systems (NIS 500k) and Rafael; DFSL LADAR ~99% detection accuracy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/0001213900-26-052213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390026052213/ea0289209-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-052213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer